Raymond James initiated coverage of Nuvalent (NUVL) with an Outperform rating and $105 price target The firm believes the potential for the company’s zidesamtinib and neladalkib assets are underappreciated at current share levels. The analyst views neladalkib as the the primary value driver for the stock.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent initiated with an Overweight at Piper Sandler
- Nuvalent Reports Q2 2025 Financials and Pipeline Progress
- Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating
- Nuvalent’s Promising Developments and Strong Financial Position Justify Buy Rating
- Nuvalent reports Q2 EPS ($1.39), consensus ($1.15)